866-997-4948(US-Canada Toll Free)

Investigation Report on China Idarubicin Market, 2010-2019

Published By :

China Research and Intelligence Co., Ltd. (CRI)

Published Date : Aug 2015

Category :

Manufacturing, Packaging & Detailing

No. of Pages : 30 Pages

The exact cause of leukemia is yet to be identified with interior decoration pollution, ionizing radiation, drug contamination and virus infection all being the suspect. The increasing incidence of leukemia is growing in China and the number of new cases reaches 40000 each year, among which over 85% belongs to acute leukemia.

Developed by Italian Arca-mone, idarubicin is an analog of daunorubicin with higher fat solubility. Its main metabolite works by preventing DNA unwinding. In preliminary studies, idarubicin turns out to be more effective and less toxic than DNR and DXR in treating L1210 leukemia, P338 leukemia and Gross leukemia. Since 1988, Japan has conducted clinical research on acute leukemia.

As an anti-mitosiss agent, idarubicin is used in the first line treatment of acute nonlymphoblastic leukemia (ANLL) relapse remission and the second line treatment of acute lymphoblastic leukemia (ALL).

According to CRI

Table of Content

1 Related Concepts of Idarubicin
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Idarubicin in China
2.1 Patent and Approval Information of Idarubicin in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Idarubicin Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Idarubicin Manufacturers in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Idarubicin in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Idarubicin in Chinese Hospitals in 2014
6.1 Pfizer Hisun Pharmaceutical Co., Ltd
6.2 Pharmacia&Upjohn (Italy)
6.3 Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd
6.4 Pfizer Inc. (Italy)

7 Major Manufacturers of Idarubicin in Chinese Market, 2010-2014
7.1 Pfizer Hisun Pharmaceutical Co., Ltd
7.2 Pharmacia&Upjohn (Italy)
7.3 Pfizer Inc. (Iyaly)
7.4 Nerviano Medical Science S.r.l. (Italy)

8 Market Outlook of Idarubicin in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Table

NA

List of Chart


Chart Approval Information of Idarubicin in China
Chart Idarubicin Sales in China
Chart Sales Value of Idarubicin in China, 2010-2014
Chart Sales Value of Idarubicin in Some Regions in China, 2010-2014
Chart Sales Volume of Idarubicin in China, 2010-2014
Chart Sales Volume of Idarubicin in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Idarubicin Enterprises for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Made by Pfizer Hisun in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Made by Pharmacia&Upjohn (IT) in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Made by Pharmacia&Upjohn (Suzhou) in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Injection in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Capsule in China, 2010-2014
Chart Price of Idarubicin Made by Pfizer Hisun Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Pharmacia&Upjohn (IT) in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Pharmacia&Upjohn (Suzhou) in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Pfizer (IT) in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Nerviano Medical Science S.r.l. (IT) in Some Chinese Cities in 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *